Central Nervous System News and Research

RSS

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals, Inc. today announced detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS).

14 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

CNF launches new educational website centered on infantile spasms

The Child Neurology Foundation (CNF) today announced the launch of a new educational website centered on infantile spasms (IS). The website, www.infantilespasmsinfo.org, is an educational resource developed by the CNF as one of the key components of Infantile Spasms Awareness Week.

12 Oct 2009

GF Capital Private Equity Fund purchases Airborne

Airborne, Inc., maker of dietary supplements that support immune health, today announced that it has been purchased by GF Capital Private Equity Fund, LP, a New York City-based private equity firm. Terms of the deal were not disclosed. Stockton Road Capital, LLC, advised and partnered with GF Capital with respect to this investment.

12 Oct 2009

Medical liability reform to save $54 billion over 10 years

The nation’s neurosurgeons are urging lawmakers to pay close attention to the newly released findings of the nonpartisan Congressional Budget Office (CBO) which confirm that medical liability reform does indeed reduce the use of healthcare services and will save the system money. In an October 9, 2009 letter to Senator Orrin G. Hatch (R-UT), CBO Director Douglas W. Elmendorf stated that a comprehensive set of tort reforms will reduce the nation’s deficit by $54 billion over 10 years.

12 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

Bicycling is a way to fight Parkinson's disease for an 81-year old patient

Bob Wilson is not a quitter, and the Parkinson's Center of Oregon at Oregon Health & Science University will benefit from his steely determination October 10 when he and other members of "Team Bob" mount specially constructed bicycles for a fund-raising outing at The Springs at Tanasbourne.

9 Oct 2009

Premature aging of immune system develops amyotrophic lateral sclerosis

Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel.

9 Oct 2009

American Shared Hospital Services updates on Todd Cancer Institute's proton therapy center development

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement regarding progress in the development of a proton therapy center at Todd Cancer Institute at Long Beach Memorial Medical Center.

8 Oct 2009

New Leaf Brands' initiative to find cure for MS, will sponsor a participating team for bike ride event

New Leaf Brands, a wholly owned subsidiary of Baywood International, Inc. (OTCBB: BAYW) ("Company"), today announced that the Company will sponsor a participating team in the Multiple Sclerosis/Tappan Zee Bike Ride taking place on Sunday, October 18, 2009 in Tarrytown, New York.

8 Oct 2009

Study suggest childhood cancer survivors are less likely to get married

Childhood cancer survivors typically suffer from the long-term effects of cancer treatment on physical health, and results of a new study suggest that social implications also exist, which may affect their chance of an "I do" at the altar.

8 Oct 2009

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

AVANIR Pharmaceuticals, Inc. today announced that it has received a “Notice of Allowance” from the United States Patent and Trademark Office (USPTO) announcing that it intends to grant the Company a new patent, extending the period of commercial exclusivity for its lead drug candidate Zenvia™ well into 2025.

8 Oct 2009

Scientists make significant advance towards a solution for neuronal repair

The repair of damaged nerve cells is a major problem in medicine today. A new study by researchers at the Montreal NeurologicaI Institute and Hospital (The Neuro) and McGill University, is a significant advance towards a solution for neuronal repair.

8 Oct 2009

Physical activity during adolescence decreases risk of glioma

While little is known about the causes of glioma, researchers at the National Cancer Institute have found that this rare but often deadly form of brain cancer may be linked to early life physical activity and height.

7 Oct 2009

Research finds 50 million people vaccinated against zoonotic brain infection

Research at the University of Liverpool has supported the vaccination of more than 50 million people against a zoonotic brain infection that affects thousands of children across Asia every year.

7 Oct 2009

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded a $6.3 million contract by the National Institute of Mental Health (NIMH) to conduct preclinical safety studies of promising novel ligands that will be used for brain imaging research and clinical applications.

6 Oct 2009

Central Nervous System News and Research

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

Positive results from Alkermes' ALKS 33 clinical trials announced

CNF launches new educational website centered on infantile spasms

GF Capital Private Equity Fund purchases Airborne

Medical liability reform to save $54 billion over 10 years

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

Bicycling is a way to fight Parkinson's disease for an 81-year old patient

Premature aging of immune system develops amyotrophic lateral sclerosis

American Shared Hospital Services updates on Todd Cancer Institute's proton therapy center development

New Leaf Brands' initiative to find cure for MS, will sponsor a participating team for bike ride event

Study suggest childhood cancer survivors are less likely to get married

Zenvia patent application: AVANIR Pharmaceuticals receives USPTO "Notice of Allowance"

Scientists make significant advance towards a solution for neuronal repair

Physical activity during adolescence decreases risk of glioma

Research finds 50 million people vaccinated against zoonotic brain infection

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News